摘要血管加压素属于非儿茶酚胺类血管活性药物，通过V1受体介导血管收缩，是脓毒性休克的二线治疗药物。拯救脓毒症运动成人脓毒症国际指南建议：当去甲肾上腺素剂量达到0.25~0.50 μg/（kg·min），仍然难以维持正常血压时使用血管加压素。儿童脓毒性休克的血流动力学改变与成人存在差异，血管加压素应用循证不足。本文结合近期临床研究资料，探讨血管加压素在脓毒性休克应用的启动时机、方法及临床评价，旨在为优化脓毒性休克管理提供参考。

abstractsVasopressin is a non-catecholamine agent that induces vasoconstriction via V1 receptors. It is currently regarded as a second-line vasopressor in the treatment of septic shock. According to the Surviving Sepsis Campaign Guidelines for the Management of Sepsis and Septic Shock in Adults,vasopressin is recommended when norepinephrine doses reach 0.25–0.50 μg/（kg·min）and normal blood pressure cannot be maintained. However,hemodynamic alterations in pediatric septic shock differ significantly from those observed in adults,and there is currently insufficient evidence to support the use of vasopressin in pediatric septic shock. This review,in conjunction with recent clinical research data,explored the optimal timing of initiation,methods of administration,and clinical evaluation criteria for vasopressin in septic shock,aiming to provide valuable references for the optimization of septic shock management.